Research Analysts Issue Forecasts for RCUS Q1 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Equities research analysts at HC Wainwright raised their Q1 2025 earnings estimates for shares of Arcus Biosciences in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.12) per share for the quarter, up from their previous forecast of ($1.30). HC Wainwright currently has a "Buy" rating and a $24.00 target price on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences' Q2 2025 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.97) EPS, Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($4.50) EPS, FY2027 earnings at ($4.67) EPS, FY2028 earnings at ($2.89) EPS and FY2029 earnings at ($1.96) EPS.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $36.00 million during the quarter, compared to analyst estimates of $29.38 million.

Several other equities research analysts also recently issued reports on RCUS. Bank of America lowered their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating for the company in a research report on Wednesday, February 19th. Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Arcus Biosciences in a report on Thursday, November 7th. Finally, Morgan Stanley dropped their price target on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Arcus Biosciences currently has an average rating of "Buy" and an average target price of $30.25.

Remove Ads

Arcus Biosciences Trading Down 8.1 %

NYSE:RCUS traded down $0.85 on Friday, reaching $9.65. The company's stock had a trading volume of 969,467 shares, compared to its average volume of 710,609. Arcus Biosciences has a 1-year low of $9.65 and a 1-year high of $19.69. The business's 50-day moving average price is $13.26 and its two-hundred day moving average price is $15.36. The firm has a market cap of $1.01 billion, a PE ratio of -3.06 and a beta of 0.84. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.24 and a current ratio of 5.24.

Insider Buying and Selling at Arcus Biosciences

In other news, Director Yasunori Kaneko purchased 20,000 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were purchased at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the transaction, the director now owns 28,400 shares of the company's stock, valued at approximately $285,704. This trade represents a 238.10 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Robert C. Goeltz II sold 3,594 shares of the business's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $15.00, for a total transaction of $53,910.00. Following the completion of the transaction, the chief financial officer now owns 60,138 shares in the company, valued at approximately $902,070. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 12.30% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Woodline Partners LP increased its holdings in shares of Arcus Biosciences by 1.3% during the fourth quarter. Woodline Partners LP now owns 3,523,937 shares of the company's stock valued at $52,471,000 after acquiring an additional 45,497 shares in the last quarter. Two Sigma Advisers LP grew its position in Arcus Biosciences by 35.8% in the 4th quarter. Two Sigma Advisers LP now owns 58,800 shares of the company's stock valued at $876,000 after purchasing an additional 15,500 shares during the period. Two Sigma Investments LP increased its stake in Arcus Biosciences by 8.1% during the 4th quarter. Two Sigma Investments LP now owns 146,686 shares of the company's stock valued at $2,184,000 after purchasing an additional 11,027 shares in the last quarter. Tema Etfs LLC acquired a new position in Arcus Biosciences during the fourth quarter worth $331,000. Finally, ProShare Advisors LLC lifted its stake in shares of Arcus Biosciences by 44.4% in the fourth quarter. ProShare Advisors LLC now owns 16,379 shares of the company's stock valued at $244,000 after buying an additional 5,038 shares in the last quarter. 92.89% of the stock is owned by institutional investors.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.